ArticleScientific reports2026
Vitamin D receptor (VDR) expression in osteosarcoma and its association with histological subtypes and metastasis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin D decreases tumor cell growth and invasiveness in primary malignant bone tumors in vitro.Journal of bone oncology · 2026Article
- Nutritional biomarkers regulating tumor immune microenvironment in osteosarcoma and as predictors of immune checkpoint inhibitor responses.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a primary malignant bone tumor most common in children and also occurs in older adults. Although it has several histopathological subtypes, it is generally aggressive and tends to metastasize. Vitamin D, through its active form 1,25(OH)2D3, binds to the vitamin D receptor (VDR) and influences pathways that inhibit tumor growth and metastasis. High VDR expression has been linked to better outcomes in various cancers, but its specific role in osteosarcoma is still unclear. VDR expression was evaluated immunohistochemically in paraffin-embedded osteosarcoma tissues from patients diagnosed at Dr. Sardjito General Hospital (2019–2025). VDR expression was categorized as significant or non-significant, and its relationship with histological subtype and metastasis was statistically analyzed. Fifty-seven patients were included, with a mean age of 19.91 ± 10.8 years. Conventional osteosarcoma (94.7%) and high-grade tumors (94.7%) were most common. Significant VDR expression was seen in 43.9% of cases, and metastasis occurred in 43.9% of patients. VDR expression was not linked to histological subtype (p = 0.499) or grade (p = 0.120), but it was significantly associated with metastasis (p < 0.001). Additionally, combined VDR expression and serum vitamin D levels were associated with metastasis (p = 0.040). This study shows that VDR expression is strongly associated with metastasis in osteosarcoma, especially in patients with low serum vitamin D. It suggests that VDR is a context-dependent biomarker: receptor expression without sufficient ligand indicates impaired vitamin D/VDR signaling and more aggressive tumors. Combining tumor VDR levels with systemic vitamin D status could improve metastasis risk assessment and support vitamin D-based therapies in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.